Press release
Jury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past Royalties
Liability for future sales to be determined AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today
About this update from Natera, Inc.
[{"type":"text","content":"\nLiability for future sales to be determined\n\n\n AUSTIN, Texas--(BUSINESS WIRE)--\nNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that a jury in the U.S. District Court for the District of Delaware has reached a unanimous verdict in favor of Natera in its patent infringement case against CareDx, Inc.\n\n\nThe jury awarded Natera $83.7 million in lost profits and $12.6 million in past royalties after finding that the accused CareDx products, AlloSure and AlloSeq, infringe one of the two Natera patents asserted against CareDx, and that all asserted claims of both patents are valid on various grounds. The jury also provided an advisory verdict to the judge that all asserted claims of both patents are valid under 35 U.S.C. Sec. 101. A schedule will be set for further proceedings to determine whether CareDx’s future sales of new versions of AlloSeq and AlloSure also infringe the asserted Natera patents.\n\n\nPreviously, Natera successfully invalidated all three of CareDx’s patents that were asserted by CareDx against Natera in a separate lawsuit. The invalidity of CareDx’s patents was affirmed on appeal.\n\n\nThe Company stated: “We are pleased with the jury’s verdict and will continue to deliver innovations backed by rigorous science to improve care for transplant patients.”\n\n\nNatera has more than 400 issued or pending patents across organ health, oncology and women’s health.\n\n\nAbout Natera\n\n\nNatera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 180 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.\n\n\nForward-Looking Statements\n\n\nAll statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward...